Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | KIF11 | P52732 | 6/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8359389 | 0.87 | EPAS1 (0.46) | EPAS1PPARGPPARA | |
| SCHEMBL17694914 | 0.84 | PTGS2 (0.42) | — | |
| SCHEMBL13239262 | 0.83 | PTGS2 (0.39) | EPAS1 | |
| SCHEMBL2255800 | 0.79 | RXRA (0.52) | — | |
| SCHEMBL20061708 | 0.79 | RARB (0.43) | KIF11 | |
| SCHEMBL17287535 | 0.79 | CA1 (0.52) | PPARGPPARAKIF11ADORA2AADORA1 | |
| SCHEMBL31305332 | 0.77 | EPAS1 (0.50) | EPAS1 | |
| SCHEMBL779828 | 0.77 | EPAS1 (0.50) | EPAS1 | |
| SCHEMBL27517450 | 0.77 | ADORA2A (0.46) | ADORA2AADORA1 | |
| SCHEMBL3857962 | 0.77 | ACLY (0.43) | KIF11STSACLYADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754103-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2010-07-13 | — | — | US | disclosed |
| US-7732021-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-7635505-B2 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2009-12-22 | — | — | US | disclosed |
| US-20090194738-A1 | Liquid-crystalline medium | MANABE ATSUTAKA | 2009-08-06 | — | — | US | disclosed |
| US-20080277623-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080128653-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080277623-A1 | Liquid Crystalline Medium | CHRM1, NEFM, CCNT1 | EPAS1 4116/4885PPARG 3159/4885PPARA 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.